Live SpaceX Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow Werewolf Therapeutics, Inc.

Get SEC filing alerts via email and in your feed for Werewolf Therapeutics, Inc.

HOWL

Werewolf Therapeutics, Inc.

About Werewolf Therapeutics, Inc.

Werewolf Therapeutics is a biopharmaceutical company developing innovative immunotherapies for cancer and immune-mediated diseases. Using its proprietary PREDATOR platform, it engineers conditionally activated cytokine molecules (INDUKINE) that target the tumor microenvironment, aiming to enhance efficacy while minimizing toxicity. Its pipeline includes cytokine-based therapeutics like IL-2, IL-12, IL-21, IL-18, and IL-10, designed for systemic delivery and tumor-specific activation. The company focuses on immuno-oncology, autoimmune, and inflammatory disease treatments.
This description was generated via AI from an annual report. Updated 9 months ago.

Latest SEC Filings from Werewolf Therapeutics, Inc.

1
1
Werewolf Therapeutics, Inc. Werewolf Therapeutics Reports $13.5 Million Net Loss in Q1 2026, Initiates Restructuring Plan

Via official filing (AI summary) | about 1 month ago | 0 comments

2
1
Werewolf Therapeutics, Inc. Werewolf Therapeutics Reports $60.8M Net Loss, Faces Strategic Review

Via official filing (AI summary) | 3 months ago | 0 comments

3
1
Werewolf Therapeutics, Inc. Werewolf Therapeutics Reports Q3 2025 Financial Results with $16.4M Net Loss

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
Werewolf Therapeutics, Inc. Werewolf Therapeutics Reports $17.98 Million Net Loss in Q2 2025, No Revenue Generated

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
Werewolf Therapeutics, Inc. Werewolf Therapeutics Reports $18.1 Million Net Loss and No Revenue in Q1 2025

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
Werewolf Therapeutics, Inc. Werewolf Therapeutics Reports $70.5 Million Net Loss and $1.9 Million Revenue for Fiscal Year 2024

Via official filing (AI summary) | about 1 year ago | 0 comments

7
1
Werewolf Therapeutics, Inc. Werewolf Therapeutics Reports Decline in Revenue and Net Loss in Q3 2024

Via official filing (AI summary) | over 1 year ago | 0 comments